
Conference Coverage
about 5 hours ago
New Models for Cellular Therapy Delivery: Christine Pfaff, RPh, MBALatest Content

Semaglutide Adherence Falls Once Out-of-Pocket Costs Top $75 a Month

Panel Confronts the Practical Barriers to Bringing Bispecifics Into Community Myeloma Care

All 50 States Apply for CMS's GENEROUS Model, With $64.3B in Savings Projected

FDA Adds HYPERION Data to Sotatercept-csrk Label for Early PAH

Contributor: Better Diabetes Management Starts With Sustaining the Behaviors That Drive Outcomes

Shorts










Center on Health Equity & Access
All News

Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.

Global Burden of Disease data show prevalence fell nearly 30% from 1990 to 2021, yet the number of women affected grew 9.1%.

Logistic regression beats machine learning to predict autoimmune hepatitis recurrence after liver transplantation.

A new blood test for adults as young as 40 years arrives as employers and insurers still treat Alzheimer disease as an old-age condition.

Itch and skin appearance outranked safety for 300 US adults with chronic hand eczema, but cancer risk came next.

Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.

Systematic review finds no ready blood biomarkers for psoriasis biologics, but IL-17A/IL-17F and beta-defensin 2 show promise for precision medicine.

Geeta Nayyar, MD, MBA, says AI's real health care payoff is cutting administrative friction with clean data and clinical leadership.

Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.

Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.





























